Researchers are reporting dramatic, if preliminary, results for a gene therapy treatment for an inherited muscle wasting disease. Three young boys with Duchenne muscular dystrophy who received gene therapy are now making at least 38% the normal level of dystrophin, a protein that is defective or missing in the disease, Forbes reports. In a video, a boy who could only climb one stair at a time quickly scales the same stairs after treatment, according to an investor presentation from the company Sarepta Therapeutics in Cambridge, Massachusetts. Two other companies are testing a similar treatment and one patient in these trials is reportedly doing well too, notes blogger Derek Lowe at the In the Pipeline blog, which is published by AAAS.
Read our COVID-19 research and news.